U.S. Markets close in 2 hrs 37 mins
  • S&P 500

    3,810.20
    +41.73 (+1.11%)
     
  • Dow 30

    31,264.14
    +340.00 (+1.10%)
     
  • Nasdaq

    12,809.71
    +86.24 (+0.68%)
     
  • Russell 2000

    2,145.56
    -1.37 (-0.06%)
     
  • Crude Oil

    66.00
    +2.17 (+3.40%)
     
  • Gold

    1,701.10
    +0.40 (+0.02%)
     
  • Silver

    25.21
    -0.25 (-0.99%)
     
  • EUR/USD

    1.1918
    -0.0061 (-0.5125%)
     
  • 10-Yr Bond

    1.5470
    -0.0030 (-0.19%)
     
  • Vix

    27.26
    -1.31 (-4.59%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.4344%)
     
  • USD/JPY

    108.2600
    +0.2840 (+0.2630%)
     
  • BTC-USD

    48,479.93
    -1,184.50 (-2.39%)
     
  • CMC Crypto 200

    970.20
    +27.03 (+2.87%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.79 (-0.23%)
     

Benzinga Pro's Top 5 Stocks To Watch Friday, Dec. 18, 2020: BBVA, MGNX, FDX, AMGN, CYTH

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Newsdesk
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Today's 5 Stock Ideas: 

  • Banco Bilbao Vizcaya Argentaria (BBVA) - A crypto exposure play. The company has been investing in Coinbase since 2015 and Coinbase recently filed for an IPO.

  • Macrogenix (MGNX) - The FDA is scheduled to rule on the company's biologics license application for margetuximab, which is being evaluated in combination with chemotherapy for treating patients with metastatic HER2-positive breast cancer. The PDUFA goal date is today.

  • FedEx (FDX) - FedEx reported Q2 earnings results yesterday after the close and traded lower. Shares could continue to be impacted today by the news.

  • Amgen (AMGN) - The FDA will decide on the company's BLA for ABP 798, a candidate to compete against Roche Holdings AG's Rituxan. The decision date is Dec. 19.

  • Cyclo Therapeutics (CYTH) - Maxim initiated a Buy rating with a $12 price target yesterday. Shares traded more than 40% higher pre-market today.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.